Epitenon-derived progenitor cells in tendon healing and adaptation
Epitenon-derived progenitor cells in tendon healing and adaptation
批准号:
10852086
负责人:
Anne E.C. Nichols
金额:
$7.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-15 至 2024-05-31
关键词:
AblationAdministrative SupplementAdrenal Cortex HormonesAffectAmericanAnti-Inflammatory AgentsAreaAwardBehavioralBiological MarkersBiological ProductsBiologyBiomechanicsCell Differentiation processCellsCellular biologyClinicClinicalDataData SetDependenceDepositionExhibitsFutureGenesGeneticGoalsHand StrengthHistologicHistologyImmuneInflammatoryInjuryInterventionKnock-outKnowledgeMeasurementMeasuresMediatingMethodsModelingMorphologyMusMusculoskeletal DiseasesNociceptorsNon-Steroidal Anti-Inflammatory AgentsOpioidOutcome MeasurePainPain ResearchPain managementParentsPathologyPatientsPersistent painPharmaceutical PreparationsPlayPopulationProcessPropertyProtease InhibitorPublic HealthQuality of lifeRheumatismRodentRoleSiteTendon InjuriesTendon structureTestingTimeTissuesdata reusedesignefficacy testingexperimental studyfunctional outcomesgait examinationhealingimprovedinnovationinsightknock-downmouse modelnegative affectnovelopioid usepain inhibitionpressurepreventprogenitorrecruitresponsesecondary analysissingle-cell RNA sequencingskin disorderstem cellstherapeutic targettreatment effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Pain associated with tendon injuries is an difficult clinical problem that significantly affects the overall quality of
life of affected patients. Current treatments for tendon pain are anti-inflammatory drugs (non-steroidal anti-
inflammatory drugs (NSAIDS) and corticosteroids) or opioids; however, anti-inflammatory drugs can negatively
affect the tendon healing process and long-term opioid use can lead to dependency and contributes to the
national opioid public health crisis. Thus, the need for novel, more targeted mechanisms to alleviate pain in
tendon injuries is high. The parent award seeks to define the overall role that epitenon cells play in tendon healing
using a novel driver (GLASTCreERT) to track and manipulate epitenon cells (GLASTLin) through a combination of
genetic lineage tracing, single-cell RNA-sequencing, and depletion/inhibitions studies. This administrative
supplement builds on preliminary data gathered during completion of Aim 1 of the parent award wherein we
discovered that a GLASTLin epitenon cells are the sole expressors of the peptidase inhibitor 16 (Pi16) gene, a
key non-neuronal regulator of persistent pain. This suggests that Pi16 expression by epitenon cells may be a
therapeutic target to mitigate the pain associated with tendon injury. Therefore, in parallel with the parent award,
the proposed administrative supplement will test the central hypothesis that epitenon-derived cells are primary
drivers of the tendon pain response. In supplemental experiments to Aim 2A of the parent award, we will first
identify pain-related behavioral metrics that can be used to longitudinally evaluate tendon pain in mouse models.
We will then assess how loss of Pi16 via GLASTLin epitenon cell depletion affects the pain response during
healing by a combination of histological and pain-related behavioral analyses. Successful completion of these
experiments will identify epitenon cell-derived Pi16 as a potential target by which tendon-related pain can be
alleviated and establish methods to measure tendon pain in future studies.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Epitenon-derived progenitor cells in tendon healing and adaptation
-
批准号:10640168
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2022
-
负责人:Anne E.C. Nichols
-
依托单位:
海外基金